| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 01/13/2005 | US20050008623 In vitro production of dendritic cells from CD14+ monocytes |
| 01/13/2005 | US20050008618 Composition for delivering an agent to a target cell and uses thereof |
| 01/13/2005 | US20050008614 Herpes virus; papillomas virus; skin; urogenital systems; topical applying; spray dressing |
| 01/13/2005 | US20050008612 drug and/or biological conjugates comprising water-soluble and non-peptidic polyethers, having hydrolytic stability, used for drug delivery; prodrugs |
| 01/13/2005 | US20050008611 Agent for the prevention and treatment of sexually transmitted diseases-I |
| 01/13/2005 | US20050008609 Multi-component reverse thermo-sensitive polymeric systems |
| 01/13/2005 | US20050008578 HFC solution formulations containing an anticholinergic |
| 01/13/2005 | US20050008572 Biocompatibility; sustained release |
| 01/13/2005 | US20050008568 Complex containing dithiocarbamate compound |
| 01/13/2005 | DE4423078B4 Verfahren zur Herstellung einer Carbamazepin-Arzneiform mit verzögerter Wirkstofffreisetzung A process for the preparation of a carbamazepine pharmaceutical form with delayed release of active ingredient |
| 01/13/2005 | CA2756586A1 Modulation of survivin expression |
| 01/13/2005 | CA2563362A1 Methods and compositions for maturing dendritic cells utilizing inosine-containing compounds |
| 01/13/2005 | CA2533312A1 Transdermal hormone delivery system: compositions and methods |
| 01/13/2005 | CA2531023A1 Glycoconjugates and their use as potential vaccines against infection by shigella flexneri |
| 01/13/2005 | CA2530811A1 Zeolites for delivery of nitric oxide |
| 01/13/2005 | CA2530783A1 Drop pills prepared from excipients derived from natural sources |
| 01/13/2005 | CA2530480A1 Conjugated complement cascade inhibitors |
| 01/13/2005 | CA2530393A1 Compositions and methods for the diagnosis and treatment of tumor |
| 01/13/2005 | CA2530032A1 Deployable multifunctional hemostatic agent |
| 01/13/2005 | CA2529555A1 Leukocyte internalized peptide-drug conjugates |
| 01/13/2005 | CA2527003A1 Modified antibody fragments |
| 01/13/2005 | CA2513213A1 Albumin fusion proteins |
| 01/12/2005 | EP1496095A1 Refrigerant compositions, refrigerant auxiliary compositions and uses thereof |
| 01/12/2005 | EP1496081A1 New powder composition, process for the preparation thereof and use as a thickener |
| 01/12/2005 | EP1496076A1 Hydrophilic polymer derivate with y type branch and preparation method of it medical composite comprising above compound |
| 01/12/2005 | EP1496064A1 Nitrate active principle |
| 01/12/2005 | EP1495769A1 Mannose-6-phosphate receptor mediated gene transfer into muscle cells |
| 01/12/2005 | EP1495767A1 Immunoadjuvant |
| 01/12/2005 | EP1495759A1 Solid dispersion composition |
| 01/12/2005 | EP1495758A2 Formulations and methods for treatment of mucosal associated conditions with an immune response modifier |
| 01/12/2005 | EP1495323A2 Method for cleaving and deglycosylating antibodies to promote ligand binding |
| 01/12/2005 | EP1495124A2 Smac-peptides as therapeutics against cancer and autoimmune diseases |
| 01/12/2005 | EP1495103A1 Targeted controlled delivery compositions activated by changes in ph or salt concentration |
| 01/12/2005 | EP1495075A2 Solid emulsions based on thermoplastic elastomers |
| 01/12/2005 | EP1495060A1 Cross-linked polyurethanes consisting of polytetrahydrofuran |
| 01/12/2005 | EP1495053A2 Angiopoietin-2 specific binding agents |
| 01/12/2005 | EP1495048A2 Heterogenenous protein networks crosslinked with silicone-containing links,and methos for producing them |
| 01/12/2005 | EP1495041A1 RNA INTERFERENCE MEDIATED INHIBITION OF G72 AND D-AMINO ACID OXIDASE (DAAO) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 01/12/2005 | EP1494998A2 Multiple-component solid phases containing at least one active pharmaceutical ingredient |
| 01/12/2005 | EP1494728A2 Tissue defect dressings comprising a keratin network |
| 01/12/2005 | EP1494722A1 Treatment methods for eotaxin mediated inflammatory conditions |
| 01/12/2005 | EP1494719A1 Injectable veterinary composition for small animals |
| 01/12/2005 | EP1494711A1 Methods for treating chronic obstructive pulmonary disease (copd) |
| 01/12/2005 | EP1494706A2 Antimicrobial polymer conjugates |
| 01/12/2005 | EP1494705A1 A composition and method for killing of tumours |
| 01/12/2005 | EP1494692A1 Topical pharmaceutical compositions comprising proanthocyanidins for the treatment of dermatitis |
| 01/12/2005 | EP1494690A2 Cochleates made with purified soy phosphatidylserine |
| 01/12/2005 | EP1494666A1 Orally deliverable pharmaceutical composition comprising an active compound having an aminosulfonyl group (cox-2 inhibitor), a polyethylene glycol and a free-radical scavenging antioxidant |
| 01/12/2005 | EP1494662A1 Tnp-470 polymer conjugates and use thereof |
| 01/12/2005 | EP1494659A1 Pharmaceutical composition comprising an alpha-ketoalkanoic acid ester or -amide and lactic acid or a lactic acid salt |
| 01/12/2005 | EP1494654A1 Palatable chewable tablet |
| 01/12/2005 | EP1494653A1 Sustained release pharmaceutical prepartations and methods for producing the same |
| 01/12/2005 | EP1494652A1 Excipient for use in dry powder inhalation preparations |
| 01/12/2005 | EP1494651A2 Preservation of bioactive materials by freeze dried foam |
| 01/12/2005 | EP1494650A1 Pharmaceutical formulation comprising melatonin |
| 01/12/2005 | EP1494649A1 Nanoparticulate megestrol formulations |
| 01/12/2005 | EP1494648A1 Powder formulations suitable for inhalation |
| 01/12/2005 | EP1494645A2 Method of treating mucus hypersecretion |
| 01/12/2005 | EP1494644A1 Dry powder compositions |
| 01/12/2005 | EP1494634A1 Controlled delivery patch of active ingredient |
| 01/12/2005 | EP1494633A1 Adherent n,o-carboxymethylchitosan drug delivery devices for moist tissue and methods of their use |
| 01/12/2005 | EP1494630A2 Bioadhesive drug delivery system |
| 01/12/2005 | EP1494542A1 Composition for modulating a physiological reaction or inducing an immune response |
| 01/12/2005 | EP1494536A1 Oil body associated protein compositions and methods of use thereof for reducing the risk of cardiovascular disease |
| 01/12/2005 | EP1414435B1 Crystalline composition containing escitalopram |
| 01/12/2005 | EP1365781A4 Acrochordon alleviation |
| 01/12/2005 | EP1307216A4 Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use |
| 01/12/2005 | EP1231894B1 Pharmaceutical formulations of salmeterol |
| 01/12/2005 | EP1227797B1 Solid dispersion pharmaceutical formulations |
| 01/12/2005 | EP1226212A4 Polymeric composition for solubilizing poorly water soluble drugs and process for the preparation thereof |
| 01/12/2005 | EP1194122B1 Methods for preparation of lipid-encapsulated therapeutic agents |
| 01/12/2005 | EP1194044B1 Pharmaceutical or dietetic mushroom-based compositions and their use |
| 01/12/2005 | EP1183228B1 Esters of l-carnitine or alkanoyl l-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds. |
| 01/12/2005 | EP1165037B1 USE OF NANOSCALAR WATER-SOLUBLE $g(b)-(1,3) GLUCANS |
| 01/12/2005 | EP1150686B1 Directly compressible matrix for controlled release of single daily doses of clarithromycin |
| 01/12/2005 | EP1117387B1 Coated medicament forms with controlled active substance release |
| 01/12/2005 | EP1089713B1 Temperature-sensitive liposomal formulation |
| 01/12/2005 | EP1087773B1 Vaginal active agent delivery procedures and formulations thereof |
| 01/12/2005 | EP1028712B1 Solid solution beadlet |
| 01/12/2005 | EP0977538B1 Aqueous compositions comprising a lipid and a lanolin-derived surfactant, and their use |
| 01/12/2005 | EP0958823B1 Azelastine hydrochloride-containing percutaneous preparation having good percutaneous absorbability and reduced skin irritation |
| 01/12/2005 | EP0750513B1 Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens |
| 01/12/2005 | EP0749304B9 Slow-release tablet containing diclofenac-na |
| 01/12/2005 | CN1564796A Stabilized compositions of aqueous reduced coenzyme Q solution |
| 01/12/2005 | CN1564695A Pharmaceutical formulation |
| 01/12/2005 | CN1564691A Interval drug release system of convulsion relieving agent |
| 01/12/2005 | CN1564689A Oral pharmaceutical products containing 17beta-estradiol-3-lower alkanoate, method of administering the same and process of preparation |
| 01/12/2005 | CN1564681A Treatment of nail infections using NO generating compositions |
| 01/12/2005 | CN1564679A Orally administered liquid compositions comprising guaifenesin and a polyoxyalkylene block copolymer |
| 01/12/2005 | CN1564678A Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy |
| 01/12/2005 | CN1564677A Aqueous dispersion comprising stable nanoparticles of a water-insoluble active and an excipient like middle chain triglycerides (MCT) |
| 01/12/2005 | CN1563308A Antianxity effect of egg of Rana Cnensinensis and preparation method |
| 01/12/2005 | CN1563306A Grease of fructus cannabis, preparation method and application |
| 01/12/2005 | CN1563154A Method for preparing variable suspensoid effect from fine particles sensitive to temperature |
| 01/12/2005 | CN1562374A fExternal substrate material for attendance of health care |
| 01/12/2005 | CN1562373A Method for preparing solid dosage forms type microsphere of alcohol soluble protein from source of plants |
| 01/12/2005 | CN1562372A Method for enwrapping matter by using intellecturalized hydrogel |
| 01/12/2005 | CN1562371A Bilogical product of anti-corrosion agent containing merthiolate in ultralow density |
| 01/12/2005 | CN1562361A Compound pefusion for anti bladder cancer |
| 01/12/2005 | CN1562356A Biological degradable macromolecule microspheres of carrying insulin and preparation method |